IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3003
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$0
Feng Zhou
China SXT Pharmaceuticals, Inc. engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company was founded in 2005 and is based in Taizhou, China.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$SXTC China SXT Pharmaceuticals, Inc. | 44 | 38 | 21 | 42 | - | - | -85.6% | -61.0% | 21.1% | -154.0% | -189.8% | - | - | 5.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
China SXT Pharmaceuticals, Inc. (SXTC) receives a "Reduce" rating with a composite score of 43.8/100. It ranks #3003 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SXTC.
View All RatingsROE proxy -85.6% (sector -1.9%)
GM 21% vs sector 44%, OM -154% vs sector 3%
Capital turnover N/A
Rev growth N/A, 7yr history
Interest coverage -4.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate China SXT Pharmaceuticals, Inc. (SXTC) as a Reduce with a composite score of 43.8/100 at a current price of $2.26. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
China SXT Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.8/100 places it at rank #3003 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
China SXT Pharmaceuticals, Inc. represents a reduce based on multi-factor quantitative performance.
China SXT Pharmaceuticals, Inc. receives a Reduce rating from our analysis, with a composite score of 43.8/100 and 2 out of 5 stars, ranking #3003 out of 7,333 stocks. SXTC's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
SXTC's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -85.6% (sector avg: -1.9%), gross margins of 21.1% (sector avg: 44.1%), net margins of -189.8% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
SXTC registers a value score of just 21/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.13x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 52/100, SXTC exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -61.0% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
SXTC is currently showing below-average momentum at 42/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of -23.76 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
SXTC's stability score of 25/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -23.76 and a debt-to-equity ratio of 5.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 51/100 for SXTC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 5.00x), micro-cap liquidity risk. With a $0 market cap (micro-cap), China SXT Pharmaceuticals, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
China SXT Pharmaceuticals, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3003 of 7,333 overall (59th percentile). Key comparisons include ROE of -85.6% trailing the -1.9% sector median and operating margins of -154.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SXTC currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (21) would have the largest impact on the composite score.
ROE 4405% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 52% BELOW SECTOR MEDIAN
Op. Margin 6234% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced as part of its Artificial Intelligence (AI) Insight

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024. Edible Garden AG Incorporated (NASDAQ: EDBL) gained 112% to $9.73 after the company reported preliminary first quarter FY24 results. Sintx Technologies, Inc. (NASDAQ: SINT) jumped 53% to $0.0350. VIA optronics AG (NYSE: VIAO) shares gained 50.4% to $0.3924 after dipping over 15% on Tuesday. AERWINS Technologies Inc. (NASDAQ: AWIN) jumped 42.2% to $4.70. The Children's Place, Inc. (NASDAQ: PLCE) climbed 35.5% to $9.64 after the company announced it entered into a new financing agreement with Mithaq Capital. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) gained 32% to $5.38 after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider. EZGO Technologies Ltd. (NASDAQ: EZGO) gained 28% to $2.20. EZGO entered into a strategic cooperation framework agreement with Woteam to jointly explore the Southeast Asian Market. CXApp Inc. (NASDAQ: CXAI) shares rose 25% to $4.89 after the company announced 24% ARR growth in 2023. TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) rose 19.6% to $2.0461. WiSA Technologies, Inc. (NASDAQ:

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results. The company said quarterly revenue surged 397% year-over-year to $1,381,754, from $278,142 in the year-ago period, according to data from Benzinga Pro. INVO Bioscience shares jumped 73.1% to $1.35 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Mobile Global Esports Inc. (NASDAQ: MGAM) shares gained 36.1% to $0.1565 in pre-market trading after falling around 9% on Tuesday. On April 16, Maxim Group analyst Jack Vander Aarde downgraded Mobile Global Esports from Buy to Hold. Chromocell Therapeutics Corporation (NYSE: CHRO) gained 29.1% to $2.35 in pre-market trading after falling around 7% on Tuesday. Clene Inc. (NASDAQ: CLNN) gained 27.9% to $0.3965 in pre-market trading after the company announced Phase 2 VISIONARY-MS long term extension study results at the 2024 American Academy of Neurology Annual Meeting. VIA optronics AG (NYSE: VIAO) shares ...

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Skillsoft posted adjusted loss of $3.09 per share, versus market estimates of $3.27 per share. The company’s quarterly sales came in at $137.540 million versus expectations of $141.897 million. Skillsoft shares dipped 26.7% to $6.74 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers WiSA Technologies, Inc. (NASDAQ: WISA) jumped 85% to $3.2379 after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand. Palisade Bio, Inc. (NASDAQ: PALI) shares climbed 79.1% to $7.45 after the company announced the completion of analysis evaluating ex-vivo bioactivation of PALI-2108. Jaguar Health, Inc. (NASDAQ: JAGX) shares gained 67% to $0.1989 after the company signed an exclusive 5-year in-license agreement with Venture Life Group for Gelclair. Dynatronics Corporation (NASDAQ: DYNT) shares rose 44.4% to $0.5342 after dipping over 5% on Monday. IMAC Holdings, Inc. (NASDAQ: BACK) surged 40% to $4.69. Peraso Inc. (NASDAQ: PRSO) gained 38.8% to $1.75. Peraso recently announced that it received an additional $2.88 million purchase order. Macatawa Bank Corporation (NASDAQ: MCBC) rose 38.8% to $13.78 after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 29.9% to ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Longboard Pharmaceuticals shares jumped 199.7% to $18.07 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Akso Health Group (NASDAQ: AHG) surged 85% to $1.2946. Polished.com Inc. (NYSE: POL) gained 45% to $8.77. Dogness (International) Corporation (NASDAQ: DOGZ) jumped 40% to $7.42. Cue Health Inc. (NASDAQ: HLTH) gained 36.8% to $0.2224 after falling 42% on Friday. Voyager Therapeutics, Inc. (NASDAQ: VYGR) surged 34% to $11.38 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington's disease and spinal muscular atrophy. RiskOn International, Inc. (NASDAQ: ROI) shares climbed 33.5% to $0.4450 after gaining around 17% on Friday. RiskOn International recently said it expects to announce its new generative AI platform and unveil a principal technology partner on Jan. 3. Soligenix, Inc. (NASDAQ: SNGX) shares gained 33.4% to $1.01. Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses. SenesTech, Inc. (NASDAQ: SNES) gained 22.2% to $1.56. SenesTech announced the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of EvolveTM. Brooge Energy Limited (NASDAQ: BROG) jumped 17.1% to $4.31. Brooge Energy recently announced that it reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations. Lyell Immunopharma, Inc. (NASDAQ: LYEL) gained 16.9% to $2.26. Wheels Up Experience Inc. (NYSE: